BRIEF-Tetraphase Pharmaceuticals Announces Everest
Post# of 31
June 4 (Reuters) - Tetraphase Pharmaceuticals Inc:
* TETRAPHASE PHARMACEUTICALS ANNOUNCES EVEREST MEDICINES’ SUBMISSION OF AN INVESTIGATIONAL NEW DRUG APPLICATION FOR ERAVACYCLINE IN COMPLICATED INTRA-ABDOMINAL INFECTION TO THE CHINA FOOD AND DRUG ADMINISTRATION
* TETRAPHASE PHARMACEUTICALS - AS A RESULT OF IND SUBMISSION, TETRAPHASE WILL RECEIVE A MILESTONE PAYMENT OF $2.5 MILLION
* TETRAPHASE - PER TERMS OF DEAL, CO MAY RECEIVE FUTURE CLINICAL, REGULATORY MILESTONES OF UP TO $14 MILLION AS WELL AS SALES MILESTONES OF UP TO $20 MILLION
* TETRAPHASE-IS ELIGIBLE TO RECEIVE DOUBLE-DIGIT TIERED ROYALTIES ON NET SALES OF ERAVACYCLINE IN CHINA, TAIWAN,HONG KONG, MACAU, SOUTH KOREA, SINGAPORE
Tetraphase Pharmaceuticals Inc. (TTPH) Stock Research Links
CLICK TO --> JOIN US RIGHT HERE